Richard A. Paulson Karyopharm Therapeutics Inc. (KPTI) insider trading activity

Richard A. Paulson is President and CEO of Karyopharm Therapeutics Inc.. Currently has a direct ownership of 1.13 Million shares of KPTI, which is worth approximately $996,100. The most recent transaction as insider was on Mar 01, 2023, when has been sold 33,033 shares (Common Stock) at a price of $3.03 per share, resulting in proceeds of $100,089. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.13M

0.96% 3M change

43.07% 12M change

Total Value Held $996,100

Richard A. Paulson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 01 2023	SELL Open market or private sale	$100,089 $3.03 p/Share	33,033 Reduced 3.86%	823,622 Common Stock
Feb 28 2023	BUY Grant, award, or other acquisition	-	252,000 Added 22.73%	856,655 Common Stock
Feb 06 2023	SELL Open market or private sale	$13,430 $3.4 p/Share	3,950 Reduced 0.65%	604,655 Common Stock
Jan 04 2023	SELL Open market or private sale	$12,824 $3.27 p/Share	3,922 Reduced 0.64%	608,605 Common Stock
Dec 05 2022	SELL Open market or private sale	$18,043 $5.17 p/Share	3,490 Reduced 0.57%	612,527 Common Stock
Nov 04 2022	SELL Open market or private sale	$15,858 $4.54 p/Share	3,493 Reduced 0.56%	616,017 Common Stock
Oct 04 2022	SELL Open market or private sale	$20,475 $5.87 p/Share	3,488 Reduced 0.56%	619,510 Common Stock
Sep 08 2022	SELL Open market or private sale	$18,265 $5.25 p/Share	3,479 Reduced 0.56%	622,998 Common Stock
Aug 04 2022	SELL Open market or private sale	$10,367 $4.48 p/Share	2,314 Reduced 0.37%	626,477 Common Stock
Jul 08 2022	SELL Open market or private sale	$10,956 $5.18 p/Share	2,115 Reduced 0.34%	628,791 Common Stock
Jun 07 2022	SELL Open market or private sale	$14,642 $5.76 p/Share	2,542 Reduced 0.4%	630,906 Common Stock
May 04 2022	SELL Open market or private sale	$178,138 $6.25 p/Share	28,502 Reduced 4.31%	633,448 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	288,750 Added 30.37%	661,950 Common Stock
May 03 2021	BUY Grant, award, or other acquisition	-	373,200 Added 50.0%	373,200 Common Stock

Also insider at

BLUE

bluebird bio, Inc. Healthcare

RAP